IQuest Enterprises, a multi-sector investment group, will purchase Viatris' active pharmaceutical ingredients (API) business in India for an undisclosed sum. As per IQuest Enterprises, the investment firm has entered into a binding deal to acquire...
As per top corporate executive, Novo Nordisk India Pvt. Ltd, the local affiliate of Danish pharmaceutical multinational Novo Nordisk, is in early talks with Torrent Pharmaceuticals Ltd to expand their manufacturing relationship...
HitGen Inc. established a collaboration with The Structural Genomics Consortium (SGC), a public-private partnership dedicated to the development of novel therapeutics through open-access research. HitGen will evaluate under-represented targets...
BDR Pharmaceutical, a major pharmaceutical business, has announced the introduction of Zisavel capsules, the first-of-its-kind generic medicine for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the isavuconazole...
The FDA has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis caused by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide). Ryzumvl is projected to...
Biosimilars, akin to their originator biologics, offer a promising avenue for addressing the complex needs of individuals battling chronic illnesses
Global pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its Nagpur Unit-1 manufacturing facility that...
Everest Medicines, a biopharmaceutical company focused on the development, manufacturing, and commercialization of novel medicines and vaccines, announced that the Taiwan Food and Drug Administration (TFDA) has approved the New Drug Applica...
Sun Pharmaceutical Industries Ltd announced an MXN 161.85 million (about Rs 75 crore) acquisition of local partner Indi Pharma from its Mexican branch. Sun Pharmaceutical Industries stated in a regulatory filing that it has signed a binding letter...
The market for mycobacterium tuberculosis tests in India is expected to grow at a compound annual growth rate of 4% between 2023 and 2033 as the country works to combat tuberculosis, a persistent global health challenge that continues to...
, CDSCO.jpg)
